These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35222509)

  • 1. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.
    Cabibbo G; Reig M; Celsa C; Torres F; Battaglia S; Enea M; Rizzo GEM; Petta S; Calvaruso V; Di Marco V; Craxì A; Singal AG; Bruix J; Cammà C
    Liver Cancer; 2022 Jan; 11(1):75-84. PubMed ID: 35222509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis.
    Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Grimaudo S; Matranga D; Attanasio M; Bruzzi P; Craxì A; Cammà C
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32752060
    [No Abstract]   [Full Text] [Related]  

  • 3. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y
    Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Niizeki T; Tokunaga T; Takami Y; Wada Y; Harada M; Shibata M; Nakao K; Sasaki R; Hirai F; Shakado S; Yoshizumi T; Itoh S; Yatsuhashi H; Bekki S; Ido A; Mawatari S; Honda K; Sugimoto R; Senju T; Takahashi H; Kuwashiro T; Maeshiro T; Nakamuta M; Aratake Y; Yamashita T; Otsuka Y; Matsumoto S; Sohda T; Shimose S; Murotani K; Tanaka Y
    Target Oncol; 2022 Nov; 17(6):643-653. PubMed ID: 36272060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
    Celsa C; Cabibbo G; Pinato DJ; Di Maria G; Enea M; Vaccaro M; Battaglia S; Rizzo GEM; Giuffrida P; Giacchetto CM; Rancatore G; Grassini MV; Cammà C
    Liver Cancer; 2024 Apr; 13(2):169-180. PubMed ID: 38751554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Li Y; Liang X; Li H; Chen X
    Cancer; 2022 Nov; 128(22):3995-4003. PubMed ID: 36111952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
    Shimose S; Sugimoto R; Hiraoka A; Tanaka M; Iwamoto H; Tanaka Y; Tada F; Ohama H; Niizeki T; Shirono T; Moriyama E; Noda Y; Kamachi N; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Hepatol Res; 2023 Feb; 53(2):116-126. PubMed ID: 36316794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
    Chihiro K; Kawaoka T; Uchikawa S; Kinami T; Yamasaki S; Kosaka M; Johira Y; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Teraoka Y; Uchida T; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Imamura M; Aikata H; Oka S
    Oncology; 2023; 101(8):491-501. PubMed ID: 37429266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
    Maesaka K; Sakamori R; Yamada R; Doi A; Tahata Y; Miyazaki M; Ohkawa K; Mita E; Iio S; Nozaki Y; Yakushijin T; Imai Y; Kodama T; Hikita H; Tatsumi T; Takehara T
    Hepatol Res; 2022 Jul; 52(7):630-640. PubMed ID: 35417606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Chiang CL; Chan SK; Lee SF; Choi HC
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
    Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
    JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
    Falette-Puisieux M; Nault JC; Bouattour M; Lequoy M; Amaddeo G; Decaens T; Di Fiore F; Manfredi S; Merle P; Baron A; Locher C; Pellat A; Coriat R
    Ther Adv Med Oncol; 2023; 15():17588359231189425. PubMed ID: 37547443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
    Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
    Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
    Singal AG; Özgürdal K; Fan X; Vassilev Z; Pan X; Multani JK; Chen CC; Zhou Z; He J; Pisa F
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
    Gordan JD; Kennedy EB; Abou-Alfa GK; Beg MS; Brower ST; Gade TP; Goff L; Gupta S; Guy J; Harris WP; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Knox JJ; Kortmansky J; Leaf A; Remak WM; Shroff RT; Sohal DPS; Taddei TH; Venepalli NK; Wilson A; Zhu AX; Rose MG
    J Clin Oncol; 2020 Dec; 38(36):4317-4345. PubMed ID: 33197225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
    J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
    Kinami T; Uchikawa S; Kawaoka T; Yamasaki S; Kosaka M; Johira Y; Yano S; Amioka K; Naruto K; Yamaoka K; Fujii Y; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Oka S
    Cancer Med; 2024 Mar; 13(5):e7025. PubMed ID: 38477514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.
    Zhang L; Xue J; Zhang N; Wang Y; Yang X; Wang S; Piao M; Liu K; Zhu C; Wang Y; Chao J; Ning C; Zhang X; Xun Z; Li Y; Sun H; Yang X; Zhao L; Zhao H
    Am J Cancer Res; 2023; 13(8):3582-3590. PubMed ID: 37693157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.